Business Context and Reporting Period
Company: NanoViricides, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 8, 2017
Event: Entry into a Material Agreement regarding the conversion of Series B Convertible Debentures.
Key Financial Metrics and Transaction Details
- Debt Conversion: $5,000,000 principal plus $27,178 accrued interest converted into 4,359,656 restricted common shares.
- Conversion Price: $1.1533 per share for principal (based on VWAP from Dec 15, 2016 to Jan 30, 2017); closing price for interest.
- Cash Repayment: Remaining $1,000,000 principal plus accrued interest to be repaid in cash.
- Total Debt Addressed: $6,000,000 aggregate principal value of Series B Debentures.
- Liquidity Impact: Company retains $5,000,000 in cash; current liabilities decrease by approximately $6,000,000.
- Transaction Costs: No commissions or fees paid other than usual attorneys' fees.
Material Changes Versus Prior Period
This filing reports a specific capital structure event rather than a periodic financial performance update. The material change is the reduction of current liabilities by approximately $6,000,000 and the issuance of new equity to satisfy $5,000,000 of that obligation. The filing text does not provide comparative revenue, profit, or margin data for prior periods.
Management Commentary, Risks, and Unusual Items
- Management Rationale: The conversion was deemed in the best interests of shareholders to bolster available capital for the current business plan.
- Related Party Transaction: Holders included an entity controlled by Board member Dr. Milton Boniuk and the Boniuk Charitable Foundation. Dr. Boniuk abstained from voting on the conversion price recommendation.
- Waivers: Holders waived all prepayment, redemption, and conversion rights under the original debentures in full satisfaction of the transaction.
- Regulatory Status: Securities were sold unregistered under Section 4(2) of the Securities Act and Rule 506 of Regulation D to accredited investors.
Investor Verification Checklist
- Verify the issuance of 4,359,656 new restricted shares and the resulting dilution impact on existing shareholders.
- Confirm the cash outflow required to repay the remaining $1,000,000 principal and accrued interest to non-converting holders.
- Review the "Conversion and Settlement Agreement" (Exhibit 10.1) for specific covenants or restrictions on the new shares.
- Assess the company's remaining liquidity position post-transaction to ensure sufficient working capital for operations.